at Zacks.com (Thu, 10:51AM)
UBS says the recent weakness in Celgene (CELG -0.6%) presents a buying opportunity. The firm believes the pullback following the company's disappointing Q1 results is due to transient issues, and the company is still on track for Q2. The firm maintains its buy rating on the shares.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Thu, 8:59AM)
at Zacks.com (Tue, 4:45PM)
at Zacks.com (Jan 22, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs